Physician profile
Deepa Jayakrishnan
NPI 1861872608
$1,974.94
in general payments reported to CMS, 2019-2025
21 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $71.56 · 2022: $400 · 2023: $439 · 2024: $564 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $250.17 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Daiichi Sankyo INC. | $208.36 | 2023-2025 | Injectafer |
| Glaxosmithkline, LLC. | $190.51 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.51 | 2022-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $184.33 | 2022-2025 | |
| Pfizer INC. | $154.22 | 2022-2025 | |
| Exact Sciences Corporation | $125.14 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $106.57 | 2019-2023 | Proquad, Vaxelis, Vaxneuvance |
| Abbvie INC. | $100.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $83.15 | 2019-2023 | Breztri |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.65 | 2022 | |
| Dexcom, INC. | $66.09 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $54.20 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $51.56 | 2019-2024 | |
| Hologic Sales and Service, LLC | $47.76 | 2024 | Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2023 | |
| Cipher Pharmaceuticals US LLC | $17.89 | 2025 | Natroba, Spinosad |
| Cranial Technologies, INC | $14.96 | 2024 | Doc Band |
| Xeris Pharmaceuticals, INC. | $14.22 | 2023 | Gvoke Hypopen |
| Organon LLC | $14.04 | 2022 | |
| Scilex Pharmaceuticals INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Jayakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.